Search
Researchers at Memorial Sloan Kettering (MSK) reported results, which were highlighted at the American Society of Clinical Oncology (ASCO) press cast, that eight weeks of acupuncture or cognitive behavioral therapy for insomnia (CBT-I) decreased the severity of insomnia in cancer survivors. While both acupuncture and CBT-I resulted in clinically meaningful and durable effects among this group, CBT-I was more effective, especially among people with mild insomnia symptoms.
New findings from a Decision Analysis for the US Preventative Services Task Force (USPSTF) suggest that routine colorectal cancer screenings can be stopped in patients over the age of 75.
When an immune cell faces a foe, it has more than chemical weapons at its disposal.
Learn about how the immunotherapies ipilimumab (Yervoy®) and nivolumab (Opdivo®) could provide a new option for patients with metastatic renal cell carcinoma.
A generous gift provides a major boost to translational research at MSK.
Physician-in-Chief Lisa M. DeAngelis joins healthcare experts during the AACR Virtual Meeting: COVID-19 and Cancer to discuss how to safely bring patients to the clinic so they can receive vital cancer screenings and care.
Scientists came to give talks and celebrate the achievements that the program has made under the leadership of Kathryn Anderson.
New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).
Learn about the breast cancer type called ductal carcinoma in situ (DCIS) and how doctors decide on the best treatment for each person.
While there has been remarkable progress in the number of people surviving with stage 4 cancer, MSK remains dedicated to research that will spur much needed advances.